dc.description.abstract | Introduction and Background
Cholestasis, or impaired bile flow, is one of the most common and devastating manifestations of hereditary and acquired liver diseases. Cholestasis of infancy, manifesting as conjugated hyperbilirubinemia, accounts 50% of the work load in tertiary referral centers for pediatric hepatology and is a common disorder for children in Taiwan. Chinese infants have a higher incidence of biliary atresia than Japanese, Philippino, and white infants. Intrahepatic cholestasis is even more common than biliary atresia in Chinese infants. Patients usually manifest by conjugated hyperbilirubinemia within the first 2 months of age. Clinical manifestations include jaundice, light-yellowish or clay-color stool, small for age, poor feeding, and hepatosplenomegaly.
Infantile cholestasis consisted of extrahepatic cholestasis and intrahepatic cholesatsis. Extrahepatic cholestasis includes biliary atresia, choledochal cyst, and inspissated bile syndrome. Intrahepatic cholestasis consists of a diversity of etiologies, termed as “neonatal hepatitis syndrome”. The etiologies includes congenital infections (TORCHES), chromosomal anomalies (Trisomy 18, 21, etc), endocrine disorders (hypopituitarism, hypothyroidism), structural anomalies (neonatal sclerosing cholangigis, Caroli disease, ductal paucity), genetic diseases (Alagille syndrome, progressive familial intrahepatic cholestasis), and metabolic diseases (tyrosinemia, glycogen storage disease, Niemann-Pick disease, lysosomal disorders, inborn errors of bile acid synthesis).
Evaluation of the cholestatic infants remains a difficult task, owing to the diversity of cholestatic syndromes and to the obscure pathogenesis of many of these disorders. Prompt identification and diagnostic assessment of the infant with cholestasis is imperative to recognize disorders amenable either to institute specific medical therapy or effective nutritional and medical support to allow optimal growth and development.
PFIC is a group of inherited, autosomal recessive disorders with infantile onset cholestasis. Patients progress to liver cirrhosis and hepatic failure in the early childhood. Three genes causing PFIC have been cloned. Defects in FIC1 (formal genetic name ATP8B1) that encodes a P-type ATPase, and BSEP (formal genetic name ABCB11) that encodes an ABC transporter, are found in patients with low serum GGT levels. Mutations in class III-multidrug-resistance P-glycoprotein (its formal genetic name ABCB4) are responsible for a distinct type of PFIC characterized by high serum GGT levels. Patients with phenotype of PFIC have been described in Japan but no reports about Chinese patients.
There has been no report about children of PFIC in Taiwan. About half of our cases with neonatal hepatitis were attributed to CMV infection and the other half were idiopathic. Following the clinical course of patients with neonatal hepatitis revealed that most cases recovered within 6 months. However, some patients progressed to liver cirrhosis and died in the early childhood. Only a few of them had a family history of infantile cholestatic jaundice. It is not known whether hereditary cholestatic syndrome with the above mentioned genetic abnormalities existed in our patients. Comprehensive studies are impeded by the laborious genetic analysis, which is available in only a few research centers in the world.
Our study started with identifying the patients with genetic disorders in Taiwan. These patients were previously classified as idiopathic. The diagnosis would directly improve the treatment and management to patients. Secondly, we determined the expression patterns of human fetal and postnatal stage, to correlate with physiological cholestasis in premature and normal infants. Thirdly we apply the primary hepatocyte culture systems to identify the effect of bile acids on the expression of canalicular transporters. The system may be applied to all forms of cholestatic diseases causing by insults such as sepsis and parenteral nutrition. Because current treatment of genetic cholestatic diseases has been unsatisfactory, most patients eventually would need liver transplantation. We have tried cell therapy in a mouse model of PFIC type 2, the sPgp knockout mice, for possible new therapeutic approaches to cholesatic liver diseases.
Genetic Studies in patients with PFIC
PFIC
From 1980 to 1998, a total of 295 patients had been admitted to the Department of Pediatrics in National Taiwan University Hospital for infantile-onset intrahepatic cholestasis. Among them, 46 (15.6%) developed to chronic cholestasis. Among the 46 patients, Alagille syndrome was diagnosed in 18, inborn errors of bile acid synthesis in four, neonatal Dubin-Johnson disease in two, and tyrosinemia in one patient. No identifiable etiology was found in the remaining 21 patients, including 6 patients with high serum GGT levels (above 94U/L according to the normal range of infant in our hospital) and 15 with normal serum GGT levels.
High GGT patients
To investigate the etiology of the 6 patients with high GGT levels, either endoscopic retrograde cholangiography, magnetic retrograde cholangiography, or operative cholangiography was performed and revealed no structural anomalies of biliary trees. Needle biopsy of the liver was performed in all patients under informed consent from the parents. These patients were followed for 17 months to 16 years. The study has been approved by the institutional review board.
Neonatal onset of cholestasis was found in five patients except case 5 who presented pruritus at one year of age. The GGT levels ranged from 1.2 x to 9.8 x of normal value. Liver histology showed significant widening and fibrosis of the portal areas, with progression to liver cirrhosis. In the remaining one patients, liver histology showed frequent spotty necrosis and occasional giant cell transformation. There were no significant changes in portal areas and bile ducts in this patient.
Analyses for MDR3 gene. MDR3 gene was analyzed in all the 6 patients. Only one (case 5) had MDR3 mutation. A homozygous 719-bp deletion (nucleotide 287 to 1005 of coding sequence) of liver cDNA was found which encompassed exon 5 to 9 and led to a frameshift. We found that MDR3 mutations accounted for about 2% (1/47) of patients with infantile-onset chronic intrahepatic cholestasis in Taiwan. The only case with novel mutation in MDR3 manifested pruritus at 1 year instead of neonatal jaundice. This implies that MDR3 defect is not a common cause of high-GGT intrahepatic cholestasis in infancy, especially in neonatal cholestasis. Those patients presenting high GGT-PFIC with early onset cholestasis but without MDR3 mutation probably had inheritable disorders remaining to be clarified.
Low GGT patients
Thirteen patients whose serum GGT levels were normal or low (below 94 U/L according to the normal range of infant in our hospital were included.
Phenotype characterization
Two distinct histopathological phenotypes were identified. Group 1 included five patients (cases 1-5) and had liver histology characterized by bland cholestasis with minimal lobular disarray. Portal fibrosis was minimal to mild. Bile ducts were normal or slightly reduced in number. Group 2 included eight patients (case 6-13) and showed evident lobular disarray, marked giant cell transformation, or confluent cell necrosis accompanied by pericellular fibrosis. The grouping results from the two pathologists were identical. Group 1 patients had chronic or intermittent cholestasis and pruritus, with mild elevation of transaminase and bilirubin levels. The associated extrahepatic manifestations included diarrhea, rickets, and failure to thrive.
Group 2 patients had marked elevation of transaminase and bilirubin levels. Peak serum bilirubin, aspartate aminotransferase, and alanine aminotransferase levels were higher than those in group 1 patients, p=0.02, p=0.001, and p=0.001, respectively. All the 8 patients in group 2 had high AFP levels (range, 2.4 to 16.2 SD score). Whereas all the 5 patients in group 1 had normal AFP levels as compared with age-specific normal range. (p<0.01). Pruritus and failure to thrive were frequent.
Genotype characterization
Analyses for FIC1 gene. Seven patients had frozen liver tissues available for analyses of FIC1 gene alterations. These included 4 patients in group 1 (bland cholestasis) and 3 patients in group 2 (giant cell transformation). All the 4 group 1 patients had mutations in FIC1 gene.
Analyses for BSEP gene. cDNA sequencing was performed in 3 group 2 patients who had no mutations in FIC1 gene. A homozygous 850G→C(V284L), and a heterozygous 1-bp deletion at position 1145 was found in patient 7. The V284L mutation occurs in the intracellular loop between transmembrane spans 4 and 5. The 1145 deletion resulted in frameshift after codon 382 followed by 15 novel amino acids and protein truncation. A homozygous missense mutation 3137 G→A (G1004D) was found in case 8, which located in extracellular loop between transmembrane spans 11 and 12.
In this study, genetic cholestasis disease was found in 86% (6/7) of the patients with infantile onset chronic intrahepatic cholestasis and low serum GGT levels. All the mutations were different from that reported from the Amish, European, or Arabic descents. It is a significant finding since the frequency of genetic diseases can vary greatly in people of different ethnic background. For example, alpha-1-antitrypsin deficiency, tyrosinemia, and cystic fibrosis were rarely seen in Asian children whereas Alagille syndrome is frequent in our children. 19 This finding prompt a specific direction of clinical awareness and research effort toward Asian patients of infantile cholestasis in the future.
We found that the phenotypic diagnosis, based on clinical, serologic, and histologic features, correlated very well with genetic changes in chronic cholestatic patients with serum low-GGT levels. Two groups of patients were identified. Group 1 was characterized by normal AFP level and bland cholestasis in histology, and high frequency of FIC1 mutation (4 of 4 patients examined). In contrast, group 2 was characterized by high AFP level, giant cell transformation with lobular disarray, and high frequency of BSEP mutations (2 of 3 patients examined). We suggest that phenotypic characterization is a simple method to identify non-familial patients suspected to have FIC1 and BSEP mutations. Subsequent cDNA sequencing is useful to confirm the genetic diagnosis, and serve as a basis for genetic counseling or future gene therapy. We also have found that AFP may serve as an additional laboratory marker to differentiate patient with BSEP mutations from FIC1 mutation patients.
Dubin-Johnson Syndrome (DJS)
Four patients were included according to the clinical characteristics and hepatic pathology compatible with the diagnosis of Dubin-Johnson syndrome in the National Taiwan University Hospital. Two of the patients had an onset of cholestasis since the neonatal period, while the other two had a history of neonatal hyperbilirubinemia, which was documented since early adolescence.
Mutational analysis (DJS)
Genomic DNA analysis
Biphasic pattern of jaundice attack was observed in one patient followed for 20 years. Mutations of ABCC2 gene, including 3 compound heterozygous, and 1 heterozygous mutations were found, including deletions (2748del136, 3615del229, and Del3399-3400) and missense mutations (L441M, E1352Q, and R393W). We found that all patients diagnosed as DJS before 10 years old have mutations involve one of the two ATP-binding cassettes (ABCs) of the MRP2 (multidrug-resistance protein 2) protein.
To our knowledge, this is the first article reporting genetic analysis and long-term follow-up of neonatal DJS. DJS is rarely diagnosed in the neonatal period and only a few cases have been reported. The clinical characteristics and diagnostic investigations are similar with adolescent- or adult-onset DJS, except that more severe cholestasis and hepatomegaly may be found. All of the mutations found in our patients are novel. This is the first report of MRP2 mutations in patients of Chinese descent. The mutations are different from those reported from Japanese patients. Most reported mutations of the ABCC2 gene in DJS involve one or both ABCs. These ABCs are important for ATP binding and are highly conserved.
Together with genotype-phenotype correlations in reported childhood cases of DJS, we suggested that disruptions of functionally important ABCs domains in the MRP2/ABCC2 protein maybe related to the earlier onset of the disease. Long-term follow-up of a neonatal-onset case is mandated because DJS may have a biphasic pattern of jaundice attack, with a second attack occurring after adolescence. Careful evaluation of all cases of neonatal jaundice to rule out DJS is suggested, especially in patients with conjugated hyperbilirubinemia with mild or minimally elevated transaminase levels.
Developmental Expression of Canalicular transporters
BSEP, MRP2, and MDR3 are major hepatic canalicular transporters mediating bile salts, conjugated bilirubin, and phospholipid secretion. Before birth, BSEP and MRP2 expressions have been reported to be either undetectable or at a much lower level than the adults in rats. This study aimed to understand the expression of canalicular transporters during human development,
We investigated the expression of genes participating in bile formation and regulation. Human liver samples from fetus at gestational age 14 to 20 weeks, adult livers and liver samples of infants with biliary atresia patients were tested for mRNA expression of BSEP, MDR3, MRP2, NTCP, FIC1, and FXR genes by using real-time RT-PCR. Immunohistochemical staining of BSEP, MDR3, and MRP2 were performed on fetal and adult livers.
Fetal expression levels of all the genes tested were lower than adult levels. The mean expression levels of BSEP, MRP2 and FIC1 were 30 to 50% of adult levels. The mean expression levels of FXR were 75% of adult levels, and the mean expression levels of MDR3 and NTCP were only 6.4% and 1.8 % of adult levels, respectively. The immunohistochemical staining of the fetal liver had distinct patterns from the adult liver. In the adult liver the characteristic canalicular staining of BSEP, MRP2, and MDR3 could be seen. In the fetal liver, different staining patterns in the three proteins were noted. MRP2 showed mainly canalicular pattern, slightly fuzzier than adult staining; BSEP showed partially intracellular and partially canalicular pattern; and MDR3 showed faint intracellular pattern, only occasionally canalicular stain could be seen.
Our study presents that canalicular transporters are expressed early in the second trimester in human, which is different from the studies in rats showing that BSEP was not expressed until after birth. Many of the bile physiology studies have been performed in rodents. However, physiological differences between human and rodents should be considered. Our results showed that the time of BSEP expression correlates with the time when bile starts to flow to the intestine before 14 weeks of gestation. Although BSEP, MRP2, as well as MDR3 genes were readily expressed before birth, the localization pattern was yet distinct from mature hepatocytes. The reasons may be immature polarization of heaptocytes during development and inadequate targeting of specific proteins to the canalicular membrane.
Regulation of canalicular transporters by bile acids in primary hepatocyte cultures
In primary hepatocyte culture systems, we found that expression of canalicular transporters gradually decreased with time in primary hepatocyte cultures after 7~14 days. After adding bile satls into culture medium, expression of BSEP (bile salt export), FIC1, and NTCP was induced, implicating that these canalicular transporters may be regulated by intrahepatic bile acid levels.
Cell therapy of sPgp knockout mice, a model of chronic cholestasis and progressive familial intrahepatic cholestasis type II
Current therapy for PFIC includes palliative therapy: medical therapy (Urso), surgical therapy (partial biliary diversion); and curative therapy: liver transplantation. Major problems of liver transplantation are lack of donors and surgical risks. Cell therapy using hepatocytes or bone marrow cells in treating liver diseases had been successful in a few animal models including metabolic liver disease and partial hepatectomy model. There has been no research on cell therapy on chronic cholestasis animal model. We used green fluorescent protein (GFP) transgenic mice as donors for cell therapy. Isolated hepatocytes were infused into the spleen of sPgp knockout mice; in another study , and bone marrow cells were infused into tail vein in sPgp knockout mice with lethal dose irradiation (700~900 rad). We found that 4 to 8 weeks after hepatocyte transplantation, scattered GFP-positive cells were visible in the liver, especially peri-portal areas. sPgp immunofluorescent staining revealed no positive-stained cells. In mice with bone marrow transplantation, donor cells comprosed about 10 % of recipient liver DNA. Most cells were spindle shaped and were Kupffer cells. Some scattered hepatocytes could be identified. In sPgp knockout mice approximately 1 in 3520 hepatocytes were donor origin, but only 1 in 13863 hepatocytes were donor origin in wild type mice, indicating a higher rate of donor cell incorporation or cell fusion in sPgp knockout mice.
The efficiency of bone marrow cells and hepatocytes repopulated in sPgp knockout mice liver was low, probably due to high endogenous regeneration activity. Further efforts in increasing donor cell repopulation and investigate the function restored by transplanted cell is mandatory. | en |
dc.relation.reference | 參考文獻
1. Alagille D, Estrada A, Hadchouel M, Gautier M, Odierre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): Review of 80 cases. J Pediatr 1987; 110:195-200.
2. Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J Pediatr Gastroentol Nutr 1994; 18:128-133.
3. Alvarez L, Jara P, Sanchez-Sabate E, Hierro L, Larrauri J, Diaz MC, Camarena C, De La Vega A, Frauca E, Lopez-Collazo E, Lapunzina P. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet 2004; 13:2451-60.
4. Amedee-Manesme O, Bernard O, Brunelle F, Hadchouel M, Polonovski C, Baudon JJ, Beguet P, Alagille D. Sclerosing cholangitis with neonatal onset. J Pediatr 1987; 111:225-229.
5. Baker AJ. Portmann B. Westably D. Wilkinson M, Karani J, Mowat AP. Neonatal sclerosing cholangitis in two siblings: a category of progressive intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 1993; 17:317-322.
6. Balistreri WF, Heubi JE, Suchy FJ. Bile acid metabolism: relationship of bile acid malabsorption and diarrhea. J Pediatr Gastroenterol Nutr 1983; 2:105-121.
7. Bergstrand CG. Alfa-fetoprotein in paediatrics. Acta Paediatr Scand 1986; 75:1-9.
8. Bieche I, Onody P, Laurendeau I, Olivi M,Vidaud D, Lidereau R, et al. Real-time reverse transcription–PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999; 45(8 Pt 1):1148–56.
9. Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 1988; 401-411.
10. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. Serum a-fetoprotein in patients with massive hepatic necrosis. Gastroenterology 1977; 72:479-82.
11. Bull LN, Carlton VE, Stricker NL, Baharloo S, DeYoung JA, Freimer NB, Magid MS, Kahn E, Markowitz J, DiCarlo FJ, McLoughlin L, Boyle JT, Dahms BB, Faught PR, Fitzgerald JF, Piccoli DA, Witzleben CL, O'Connell NC, Setchell KDR, Agostini RM, Kocoshis SA, Reyes J, Knisely AS. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler Disease [PFIC-1] and Byler syndrome): Evidence for heterogeneity. Hepatolology 1997; 26:155-164.
12. Bull LN, van Eijk MJT, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nature genetics 1998; 18:219-224.
13. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002; 123:1649-58.
14. Chang MH, Hsu HC, Lee CY, Wang TR, Kao CL. Neonatal hepatitis: a follow-up study. J Pediatr Gastroenterol Nutr 1987; 6:203-207.
15. Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, Knisely AS, Strautnieks SS, Thompson RJ, Magid MS, Gordon R, Balasubramanian N, Suchy FJ, Shneider BL.Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor . Gastroenterology 2004; 126:756-764.
16. Childs S, Yeh RL, Georges E, Ling V. Identification of a sister gene to P-glycoprotein. Cancer Res 1995; 55:2029-2034.
17. Chiu HH, Chang MH, Chen HL, Hsu HY, Ni YH. Paucity of interlobular bile ducts in Chinese children. J Gastroentrol Hepatol 1996; 11:434-438.
18. Chuang E and Harber BA. Bile secretion and its control in the mature and immature organism. In Polin RA, Fox WW Eds. Fetal and Neonatal Physiology. Philadelphia W.B. Saunders 1998, pp 1457-1471.
19. Clayton RJ. Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 1969; 117:112-124.
20. Colombo C, Zuliani G, Ronchi M, Breidenstein J, Setchell KDR. Biliary bile acid composition of the human fetus in early gestation. Pediatr Res 1987; 21:197-200.
21. de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze J-F, Desrochers M, Burdelski M, Bernard O, Oude Elferink RPJ, Hadchouel M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998; 95:282-287.
22. De Wolf-peeters C, De Vos R, Desmet V. Electron microscopy and histochemistry of canalicular differentiation in fetal and neonatal rat liver. Tissue Cell 1972; 4:379-388.
23. Deeley RG, Cole SP. Function, evolution, and structure of multidrug resistance protein (MRP). Semin Cancer Biol 1997; 8:193-204.
24. Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, Hadchouel M 1996 Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996; 23:904-908.
25. Dellert SF, Balistreri WF: Neonatal cholestasis. In Walker WA, eds. Pediatric Gastrointestinal disease. Volume 2. 2rd ed. Mosby-Year Book, 1996, 999-1016.
26. Drouin E, Mitchell GA, Rasquin-Weber A. Other Inherited Cholestatic Disorders. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB (Eds) Pediatric Gastrointestinal Disease. 3rd Ed. BC Decker Inc, Hamilton, Ontario 2000, pp 1211-1218.
27. Dubin IN, Johnson FB. Chronic idiopathic jaundice with unidentified pigment in liver cells: new clinicopathologic entity with report of 12 cases. Medicine 1954; 33:155-197.
28. Emond JC, Whitington PF. Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). J Pediatr Surg 1995; 30:1635-1641.
29. Eppens EF, van Mil SW, de Vree JM, Mok KS, Juijn JA, Oude Elferink RP, Berger R, Houwen RH, Klomp LW. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J Hepatol. 2001; 35:436-443.
30. Feracci H, Connolly TP, Margolis RN, Hubbard AL. The establishment of hepatocyte cell surface polarity during fetal liver development. Dev Biol 1987; 123:73-84.
31. Gao B, St Pierre MV, Stieger B, Meier PJ. Differential expression of bile salt and organic anion transporters in developing rat liver. J Hepatol. 2004; 41:201-208.
32. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998; 273:10046-10050.
33. Hagenbuch B, Steiger B, Fouget M, Lubbert H, Meier PJ. Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc. Natl. Acad. Sci. USA 1991; 88:10629-10633.
34. Haimi-Cohen Y, Merlob P, Marcus-Eidlits T, Amir J. Dubin-Johnson syndrome as a cause of neonatal jaundice: the importance of coproporphyrins investigation. Clinical Pediatrics 1998; 37:511-513.
35. Hashimoto K, Uchiumi T, Konno T, Ebihara T, Nakamura T, Wada M, et al. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002; 36:1236-1245.
36. Heubi JE, Balistreri WF, Suchy FJ. Bile salt metabolism in the first year of life. J Lab Clin Med 1982; 100:127-136.
37. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the transporter gene, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11:175-184.
38. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353:210-211.
39. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25:519-523.
40. Jansen PJ, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterol 1999; 117:1370-1379.
41. Jirsa M, Cebecauerova D, Budisova L, Chuzhanova N, Hrebicek M, Dvorakova L, Vitek L, Brodanova M, Hulek P, Taimr P. Indel in the FIC1/ATP8B1 gene-a novel rare type of mutation associated with benign recurrent intrahepatic cholestasis. Hepatol Res. 2004; 30:1-3.
42. Kagalwalla AF, Al Amir AR, Khalifa A, Sylven M, Al Ajaji S, Kagalwalla YA Progressive familial intrahepatic cholestasis (Byler's disease) in Arab children. Ann Trop Paediatr 1995; 15:321-327.
43. Kajihara S, Hisatomi A, Mizuta T, Hara T, Ozaki I, Wada I, et al. A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem Biophys Res Commun 1998; 253:454-457.
44. Kanamura S, Kanai K, Watanabe J. Fine structure and function of hepatocytes during development. J Electron Microsc Tech 1990; 14:92-105.
45. Kartenbeck J, Leuschner U, Mayer R, Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996; 23:1061-1066.
46. Kaufman SS. Organogenesis and histologic development of the liver. In Polin RA, Fox WW Eds. Fetal and Neonatal Physiology. Philadelphia W.B. Saunders 1998, pp 1433-1441.
47. Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000; 32:1317-1328.
48. Keitel V, Nies AT, Brom M, Hummel-Eisenbeiss J, Spring H, Keppler D. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am J Physiol Gastrointest Liver Physiol 2003; 284:G165-174.
49. Kikuchi S, Hata M, Fukumoto K, Yamane Y, Matsui T, Tamura A, et al. Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat Genet 2002; 31:320-325.
50. Kimura A, Ushijima K, Kage M, Mahara R, Tohma M, Inokuchi T, et al. Neonatal Dubin-Johnson syndrome with severe cholestasis: effective phenobarbital therapy. Acta Paediatr Scand 1991; 80:381-385.
51. Klomp LW, Vargas JC, van Mil SW, Pawlikowska L, Strautnieks SS, van Eijk MJ, Juijn JA, Pabon-Pena C, Smith LB, DeYoung JA, Byrne JA, Gombert J, van der Brugge G, Berger R, Jankowska I, Pawlowska J, Villa E, Knisely AS, Thompson RJ, Freimer NB, Houwen RH, Bull LN. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology. 2004; 40:27-38.
52. Kondo T, Yagi R, Kuchiba K. Dubin-Johnson syndrome in a neonate. N Engl J Med 1975; 292:1028-1029.
53. Lai MW, Chang MH, Hsu SC, Hou JW, Hsu HC, Su CT, Kao CL, Lee CY. Differential diagnosis of cholestasis in infancy: a prospective study. J Pediatr Gastroenterol Nutr 1994; 18:121-127.
54. Lee PI, Chang MH, Chen DS, Hsu HC, Lee CY. Prognostic implications of serum α-fetoprotein levels in neonatal hepatitis. J Pediatr Gastroenterol Nutr. 1990; 11:27-31.
55. Lee PI, Chang MH, Chen DS, Lee CY. Serum alpha-fetoprotein in normal Chinese infants. Acta Paed Sin 1988; 29:152-8. 18. Shneider BL. Genetic cholestasis syndromes. J Pediatr Gastroenterol Nutr 1999; 28:124-131.
56. Lincke CR, Smit JJM, Van der Velde-Koerts T, Borst P. Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 1991; 266: 5303-5310.
57. Lo NS, Chan CW, Hutchison JH. Dubin-Johnson syndrome with some unusual features in a Chinese family. Arch Dis Child 1979; 54:529-533.
58. Lykavieris P, van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, Bernard O, Jacquemin E. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 2003; 39:447-452.
59. Materna V, Lage H. Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. J Hum Genet 2003; 48:484-486.
60. Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001; 276:36923-36930.
61. Muller M and Jansen PLM. Molecular aspects of hepatobiliary transport. Am J Physiol 1997; 272:1539-1542.
62. Nakata F, Oyanagi K, Fujiwara M, Sogawa H, Minami R, Horino K, et al. Dubin-Johnson syndrome in a neonate Eur J Pediatr 1979; 132:299-301.
63. Noe J, Stieger B, Meier PJ. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology. 2002; 123:1659-1666.
64. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz IO, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS, Chandrasekharappa SC. Mutations in the human Jagged 1 gene are responsible for Alagille Syndrome. Nat Genet 1997; 16:235-42.
65. Oude Elferink RPJ, Ottenhoff R, Wijland M, Smit JJM, Schinkel AH. Groen AK. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 1995; 95:31-38.
66. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25:1539-1542.
67. Plass JRM, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PLM, et al. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 2002; 35:589-596.
68. Regev RH, Stolar O, Raz A, Dolfin T. Treatment of severe cholestasis in neonatal Dubin-Johnson syndrome with ursodeoxycholic acid. J Perinat Med 2002; 30:185-187.
69. Schinkel AH, Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991; 51:2628-2635.
70. Shani M, Seligsohn U, Gilon E, Sheba C, Adam A. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. QJM 1970; 39:549-567.
71. Shieh CC, Chang MH, Chen CL. Dubin-Johnson syndrome presenting with neonatal cholestasis. Arch Dis Child 1990; 65:898-899.
72. Shoda J, Suzuki H, Suzuki H, Sugiyama Y, Hirouchi M, Utsunomiya H, et al. Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol Res 2003; 27:323-326.
73. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L, Mol CAAM, Ottenhoff R, van der Lugh NM, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM, Bosrt P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75:451-462.
74. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner S, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nature Genetics 1998; 20:233-238.
75. Strautnieks SS, Byrne JA, Mieli-Vergani G, Knisely AS, Bull LN, Thompson RJ. Genetic Analysis of the progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutrition 2004; 39 suppl 1, S69.
76. Tate G, Li M, Suzuki T, Mitsuya T. A new mutation of the ATP-binding cassette, sub-family C, member 2 (ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Genes Genet Syst 2002; 77:117-121.
77. Tazawa Y, Yamada M, Nakagawa M, Konno T, Tada T. Bile acid profiles in siblings with progressive intrahepatic cholestasis: absense of biliary chenodeoxycholate. J Pediatr Gastroenterol Nutr 1985; 4:32-37.
78. Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999; 64:739-746.
79. Tomer G, Ananthanarayanan M, Weymann A, Balasubramanian N, Sucy FJ. Differential development regulation of rat liver canalicular membrane transporters Bsep and Mrp2. Pediatr Res 2003; 53:288-294.
80. Tsai WH, Teng RJ, Chu JS, Chang MH, Ho MM. Neonatal Dubin-Johnson syndrome. J Pediatr Gastroenterol Nutr 1994; 18:253-254.
81. Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999; 117:653-660.
82. Ujhazy P, Ortiz D, Misra S, Li S, Moseley J, Jones H, Arias IM. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 2001; 34:768-775.
83. van Kuijck MA, Kool M, Merkx GF, Geurts van Kessel A, Bindels RJ, Deen PM, et al. Assignment of the canalicular multispecific organic anion transporter gene (cMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization. Cytogenet Cell Genet 1997; 77:285-287.
84. van Mil SW, Klomp LW, Bull LN, Houwen RH. FIC1 disease: a spectrum of intrahepatic cholestatic disorders. Semin Liver Dis 2001; 21:535-544.
85. van Mil SW, van der Woerd WL, van der Brugge G, Sturm E, Jansen PL, Bull LN, van den Berg IE, Berger R, Houwen RH, Klomp LW. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology. 2004; 127:379-384.
86. Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998; 7:203-207.
87. Wakusawa S, Machida I, Suzuki S, Hayashi H, Yano M, Yoshioka K. Identification of a novel 2026G | zh_TW |